Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the...

Full description

Bibliographic Details
Main Authors: Connie A. Haley, Patricia Macias, Supriya Jasuja, Betsy A. Jones, Marie-Claire Rowlinson, Roshni Jaimon, Pennelyn Onderko, Elaine Darnall, Maria E. Gomez, Charles Peloquin, David Ashkin, Neela D. Goswami
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2021-01-01
Series:Emerging Infectious Diseases
Subjects:
tuberculosis and other mycobacteria
antimicrobial resistance
drug monitoring
bedaquiline
pretomanid
linezolid
Online Access:https://wwwnc.cdc.gov/eid/article/27/1/20-3766_article

Internet

https://wwwnc.cdc.gov/eid/article/27/1/20-3766_article

Similar Items